HC Wainwright Issues Pessimistic Estimate for BHST Earnings

Key Points

• HC Wainwright has lowered its Q3 2025 earnings per share estimate for BioHarvest Sciences from ($0.06) to ($0.10).
• In its latest earnings report, BioHarvest Sciences reported a loss of ($0.15) EPS, missing the consensus estimate of ($0.11) by ($0.04).
• BioHarvest Sciences' stock has seen a recent increase of 4.2%, trading at $9.49, with a market capitalization of $155.87 million.

BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for BioHarvest Sciences in a report released on Tuesday, August 12th. HC Wainwright analyst A. Dayal now expects that the company will post earnings per share of ($0.10) for the quarter, down from their previous forecast of ($0.06). The consensus estimate for BioHarvest Sciences' current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for BioHarvest Sciences' Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.53) EPS, FY2026 earnings at $0.04 EPS, FY2027 earnings at $0.29 EPS, FY2028 earnings at $0.64 EPS and FY2029 earnings at $1.14 EPS.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.04). The firm had revenue of $8.52 million during the quarter, compared to analyst estimates of $8.53 million. BioHarvest Sciences had a negative net margin of 39.95% and a negative return on equity of 11,357.84%.

Separately, Craig Hallum assumed coverage on BioHarvest Sciences in a report on Monday, May 5th. They set a "buy" rating and a $15.00 target price on the stock.

BioHarvest Sciences Trading Up 1.1%

Shares of NASDAQ:BHST traded up $0.10 during trading on Thursday, hitting $9.32. 74,866 shares of the company were exchanged, compared to its average volume of 15,467. The stock has a market cap of $153.08 million, a price-to-earnings ratio of -13.31 and a beta of 0.68. BioHarvest Sciences has a fifty-two week low of $4.66 and a fifty-two week high of $9.90. The firm has a fifty day moving average price of $7.41 and a two-hundred day moving average price of $6.47.

Hedge Funds Weigh In On BioHarvest Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of BHST. TD Waterhouse Canada Inc. acquired a new stake in shares of BioHarvest Sciences in the fourth quarter valued at about $69,000. True North Advisors LLC boosted its holdings in BioHarvest Sciences by 7.6% in the first quarter. True North Advisors LLC now owns 44,391 shares of the company's stock worth $275,000 after acquiring an additional 3,120 shares in the last quarter. Finally, Magnus Financial Group LLC lifted its holdings in shares of BioHarvest Sciences by 105.0% in the first quarter. Magnus Financial Group LLC now owns 71,733 shares of the company's stock valued at $444,000 after purchasing an additional 36,733 shares in the last quarter.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.